舒林酸抑制布美他尼诱导的钠和水排泄。
Sulindac inhibits bumetanide-induced sodium and water excretion.
作者信息
Skinner M H, Mutterperl R, Zeitz H J
机构信息
Max Samter Institute of Allergy and Clinical Immunology, Chicago, Ill.
出版信息
Clin Pharmacol Ther. 1987 Nov;42(5):542-6. doi: 10.1038/clpt.1987.194.
In an open-label pilot study, we investigated the effect of sulindac on bumetanide-induced diuresis. Nine healthy volunteers were placed on diets with a standard sodium and potassium content. Each volunteer received 1 mg bumetanide orally, and blood and urine samples were collected during an 8-hour period. Urinary losses were replaced isovolumetrically with intravenous normal saline solution. Creatinine clearance and sodium and potassium excretion were compared with and without sulindac pretreatment (200 mg administered orally b.i.d. for 5 days). Sulindac pretreatment resulted in a 22% decrease in the mean cumulative sodium excretion after 3 hours (p less than 0.05) and a 21% decrease in the mean urine flow rate after 2 hours (p less than 0.05). The results suggest that sulindac has an effect on the kidney similar to that of other nonsteroidal agents.
在一项开放标签的试点研究中，我们研究了舒林酸对布美他尼诱导利尿的影响。九名健康志愿者采用含标准钠和钾含量的饮食。每位志愿者口服1毫克布美他尼，并在8小时内采集血液和尿液样本。用静脉注射生理盐水等容替代尿中丢失量。比较了舒林酸预处理（口服200毫克，每日两次，共5天）前后的肌酐清除率以及钠和钾排泄情况。舒林酸预处理使3小时后的平均累积钠排泄量降低了22%（p<0.05），2小时后的平均尿流率降低了21%（p<0.05）。结果表明，舒林酸对肾脏的作用与其他非甾体类药物相似。
Zotero 插件